Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 11 hours ago

Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, applauded the enactment of a new law (HB 1123) in Pennsylvania aligning insurance coverage for colorectal cancer screening to reflect the latest American Cancer Society (ACS) and National Comprehensive Cancer Center (NCCN) guidelines, ensuring no cost-sharing for about 2 million Pennsylvanians of screening-eligible age.1The landmark legislation marks a historic moment for states proactiv.

Business Wire • 14 hours ago

Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors

After delivering results well above expectations, TWST management significantly raised its outlook and projected triple-digit growth in orders. During the quarter, LIFE shares performed well following a strong earnings beat. During the quarter, several key approvals and coverage expansions supported product growth for GH.

Seeking Alpha • Oct 28, 2026

This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga • Oct 23, 2026

Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Mad.

Business Wire • Oct 20, 2026

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.

MarketBeat • Oct 19, 2026

Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening and follow-up colonoscopy adherence at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville, Tennessee. A modeling study looking at individuals 45 to 75 over a lifetime projected.

Business Wire • Oct 15, 2026

Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast wil.

Business Wire • Oct 8, 2026

Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe's in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca's next-generation oral selective estrogen.

Business Wire • Oct 8, 2026

Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250

Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential upside toward $250 if buyers defend key breakout support.

FXEmpire • Oct 5, 2026